Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H15NO3 |
| Molecular Weight | 149.1882 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN(CCO)CCO
InChI
InChIKey=GSEJCLTVZPLZKY-UHFFFAOYSA-N
InChI=1S/C6H15NO3/c8-4-1-7(2-5-9)3-6-10/h8-10H,1-6H2
DescriptionCurator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Trolamine, an organic compound, is the salt formed between triethanolamine and salicylic acid. It is widely used as a topical analgesic. 10% trolamine salicylate medical products sold over-the-counter such as are creams for temporarily relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, lumbago, neuralgia, strains, bruises, and sprains. The FDA approved in 1958 otic solution drops containing triethanolamine polypeptide used in the ear to break down and loosen earwax was discontinued. Trolamine can enhance skin healing by recruiting macrophages and modifying the concentrations of various immunomodulators. Trolamine (Biafine; Genmedix Ltd, France) is commonly prescribed at the beginning of radiotherapy for preventing acute radiation-induced skin toxicity in China. Biafine has been studied in radiodermatitis and Phase 2 clinical trial has been initiated in 2016 by Sun Yat-sen University to establish the efficacy of trolamine (Biafine) for the management of radiation dermatitis in patients with nasopharyngeal carcinoma receiving IMRT.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | Volu-Firm Approved UseUnknown |
|||
| Palliative | CERUMENEX Approved UseFor removal of impacted cerumen prior to ear examination, otologic therapy and/or audiometry. CERUMENEX Eardrops should be used only with caution in external otitis. Launch Date1958 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 Health Status: unhealthy Age Group: 21.6–84.9 Sex: M+F Sources: |
Disc. AE: Application site erythema... AEs leading to discontinuation/dose reduction: Application site erythema (6.7%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Application site erythema | 6.7% Disc. AE |
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 Health Status: unhealthy Age Group: 21.6–84.9 Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Preliminary assessment of selected methacrylic acid--acrylic acid copolymers as factors buffering triethanolamine interacting with artificial skin sebum. | 2001 |
|
| [Enantiomeric separation of drugs with capillary electrophoresis with cyclodextrins]. | 2001 |
|
| Enantioselective separation of epoxides by capillary electrophoresis employing sulfated beta-cyclodextrin as chiral selector. | 2001 Apr |
|
| In situ hybridization: use of 35S-labeled probes on paraffin tissue sections. | 2001 Apr |
|
| Comparative studies of various run buffers for chiral capillary electrophoresis using chiral crown ether as a chiral selector. | 2001 Dec |
|
| In vitro percutaneous absorption of tenoxicam from pressure-sensitive adhesive matrices across the hairless mouse skin. | 2001 Dec |
|
| Bis(triethanolamine)cadmium(II) and -mercury(II) saccharinates: seven-coordinate complexes containing both tri- and tetradentate triethanolamine ligands. | 2001 Dec |
|
| Vanadium, molybdenum, and sodium triethanolamine complexes derived from an assembly system containing tetrathiometalate and triethanolamine. | 2001 Jul 16 |
|
| Extraction and separation of cationic surfactants from river sediments: application to a spectrophotometric determination of cationic surfactant in an aquatic environment using membrane filters. | 2001 Nov |
|
| Luminol chemiluminescence in unbuffered solutions with a cobalt(II)-ethanolamine complex immobilized on resin as catalyst and its application to analysis. | 2001 Nov 1 |
|
| [Determination of sulfite residues in foods by using the modified rankine apparatus and HPLC]. | 2001 Oct |
|
| Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. | 2002 Apr 2 |
|
| Quantitation of nicotine in tobacco products by capillary electrophoresis. | 2002 Jan-Feb |
|
| Physicochemical determinants of linear alkylbenzene sulfonate (LAS) disposition in skin exposed to aqueous cutting fluid mixtures. | 2002 Jun |
|
| Carcinostatic, protective, and adaptive activities of tris-(2-hydroxyethyl)ammonium salts of arylheteroacetic acids. | 2002 Sep-Oct |
|
| Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. | 2003 Apr 22 |
|
| The use of complexation with alkanolamines to facilitate skin permeation of mefenamic acid. | 2003 Aug 27 |
|
| A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. | 2003 Dec 1 |
|
| Patch testing with the irritant sodium lauryl sulfate (SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. | 2003 Feb |
|
| Equilibria of mononuclear oxomolybdenum(VI) complexes of triethanolamine. A multinuclear dynamic magnetic resonance study of structure and exchange mechanisms. | 2003 Jul |
|
| A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord. | 2003 Jul 25 |
|
| Photovoltaic properties of self-assembled monolayers of porphyrins and porphyrin-fullerene dyads on ITO and gold surfaces. | 2003 Jul 30 |
|
| Synthesis of uniform anatase TiO2 nanoparticles by gel-sol method. 4. Shape control. | 2003 Mar 1 |
|
| Qualitative determination of false-positive effects in the acetylcholinesterase assay using thin layer chromatography. | 2003 May-Jun |
|
| Determination of alkanolamines in cattails (Typha latifolia) utilizing electrospray ionization with selected reaction monitoring and ion-exchange chromatography. | 2004 |
|
| [The problem and improvement of colorimetric method for determination of sulfite in foods containing sulfur compounds]. | 2004 Dec |
|
| Analysis of Tamm-Horsfall protein by high-performance liquid chromatography with native fluorescence. | 2004 Feb 20 |
|
| Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines. | 2004 Jan |
|
| Quantitation of biomarkers of exposure to nitrogen mustards in urine from rats dosed with nitrogen mustards and from an unexposed human population. | 2004 Jul-Aug |
|
| Integrative analysis of the mitochondrial proteome in yeast. | 2004 Jun |
|
| Evaluation of the potential of triethanolamine to alter hepatic choline levels in female B6C3F1 mice. | 2004 Jun |
|
| Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. | 2004 May 4 |
|
| A high-nuclearity "Celtic-ring" isopolyoxotungstate, [H12W36O120]12-, that captures trace potassium ions. | 2004 Nov 3 |
|
| Functionalized metal oxide clusters: synthesis, characterization, crystal structures, and magnetic properties of a novel series of fully reduced heteropolyoxovanadium cationic clusters decorated with organic ligands--[MVIV6O6[(OCH2CH2)2N(CH2CH2OH)]6]X (M = Li, X = Cl x LiCl; M = Na, X = Cl x H2O; M = Mg, X = 2Br x H2O; M = Mn, Fe, X = 2Cl; M = Co, Ni, X = 2Cl x H2O). | 2004 Sep 20 |
|
| Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. | 2005 Feb 14 |
Sample Use Guides
Fill ear canal with ear drops of 10% triethanolamine Polypeptide Oleate-Condensate with the patient’s head tilted at a 45° angle. Insert cotton plug and allow to remain 15-30 minutes. Then gently flush with lukewarm water, using a soft rubber syringe (avoid excessive pressure). Exposure of skin outside the ear to the drug should be avoided. The procedure may be repeated if the first application fails to clear the impaction.
Route of Administration:
Otic (auricular)
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D03AX12
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
||
|
EPA PESTICIDE CODE |
4208
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2768
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL446061
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
m11100
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
TRIETHANOLAMINE
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
203-049-8
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
561
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
28621
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
SUB12376MIG
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
9O3K93S3TK
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
DTXSID9021392
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
1696958
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
38623
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB13747
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
100000079034
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
36718
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
9O3K93S3TK
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
C009546
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
7618
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
C80948
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
102-71-6
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY | |||
|
893
Created by
admin on Mon Mar 31 18:17:35 GMT 2025 , Edited by admin on Mon Mar 31 18:17:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
